Table 3. Distribution of methylated and unmethylated DUSP2 in tissues at diagnosis (N=112) according to clinicopathological characteristics of patients.
| Characteristic | DUSP2 in tissue at diagnosis (N=109)*, N (%) | DUSP2 in serum at start of treatment (N=44)§, N (%) | DUSP2 in serum at end of treatment (N=17), N (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Methylated (N=49) | Unmethylated (N=60) | P | Methylated (N=3) | Unmethylated (N=41) | P | Methylated (N=5) | Unmethylated (N=12) | P | |||
| TP53 mutation | 0.292 | 0.078 | 0.091 | ||||||||
| Wild-type | 17 (34.7) | 29 (48.3) | 3 (100.0) | 14 (34.1) | 0 | 6 (50.0) | |||||
| Disruptive | 17 (34.7) | 14 (23.3) | 0 | 16 (39.0) | 2 (40.0) | 4 (33.3) | |||||
| Non-disruptive | 15 (30.6) | 17 (28.3) | 0 | 11 (26.8) | 3 (60.0) | 2 (16.7) | |||||
| SNP72 (TP53) rs1042522 | 0.317 | 1.000 | 1.000 | ||||||||
| Arg/Arg+Arg/Pro | 38 (77.6) | 51 (85.0) | 2 (66.7) | 32 (78.0) | 4 (80.0) | 11 (91.7) | |||||
| Pro/Pro | 11 (22.4) | 9 (15.0) | 1 (33.3) | 9 (22.0) | 1 (20.0) | 1 (8.3) | |||||
Analysis not performed in 3(*) and 2(§) samples. DUSP2, dual-specificity-phosphatase-2.